News
-
-
PRESS RELEASE
Valneva Announces the Success of its Private Placement Raising approximately €60 Million
Valneva SE successfully raises approximately €60 million through a Private Placement, issuing 23,000,000 new ordinary shares. The funding will support the company's clinical programs and future growth, including the Shigella vaccine program -
-
-
PRESS RELEASE
Valneva Announces the Launch of a Private Placement of Ordinary Shares for Approximately 60 Million Euros
Valneva announces private placement of ordinary shares for 60 million Euros to fund clinical and pre-clinical programs, commercialization activities, and general corporate purposes. Accelerated book-building process underway -
-
-
-
PRESS RELEASE
Valneva et Pfizer annoncent de nouvelles données positives de Phase 2 après une vaccination de rappel pour le candidat vaccin contre la maladie de Lyme
Valneva et Pfizer rapportent des données positives de Phase 2 pour le candidat vaccin contre la maladie de Lyme, montrant une forte réponse immunitaire post-vaccination de rappel -
PRESS RELEASE
Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate
Valneva and Pfizer announce positive Phase 2 booster results for Lyme disease vaccine candidate, VLA15-221, showing strong immune response and safety profile, advancing towards Phase 3 trials
